2nd Annual Hepato-Pancreato-Biliary Symposium

Saturday, September 13, 2025, 8:00 AM - 5:00 PM, The Westin La Paloma, 3800 E Sunrise Dr., Tucson, AZ


AMA PRA Category 1 Credits™ (7.50 hours), ABS CC (7.50 hours), Non-Physician Attendance (7.50 hours)

The 2nd Annual Hepato-Pancreato-Biliary (HPB) Symposium will take place on September 13, 2025 at the Westin La Paloma, 3800 E Sunrise Dr, Tucson, AZ 85718. The conference will provide education on the care of complex Hepato-Pancreato-Biliary (HPB, including pancreas, liver, and bile duct) malignancies, with a focus on cutting-edge technology, oncologic advances, and multidisciplinary management of these complex problems. Leading experts in the fields of HPB surgery, medical oncology, surgical oncology, interventional gastroenterology, and interventional radiology will discuss the advances in pancreatic cancer, management and decision-making in pancreatic cystic lesions, and cutting-edge management of colorectal liver metastases. There will be multidisciplinary case discussions included to illustrate decision-making and engage participants across the medical community in Arizona. This conference is a great learning opportunity for general surgeons, medical oncologists, radiation oncologists, gastroenterologists, primary care physicians, colorectal surgeons, and HPB specialists who encounter these problems in their practice.

1. Describe the role of, and utilize when appropriate, complete tumor sequencing in identification of targetable mutations in pancreatic cancer to guide management.
2. Incorporate knowledge of the evolving role of circulating tumor- DNA (ct-DNA) in prognosis, decisions regarding adjuvant therapy and in detection of early recurrence.
3. Employ criteria for vascular resection in pancreatic cancer.
4. Identify pancreatic cystic lesions on cross-sectional imaging, and recognize the high-risk stigmata and worrisome features that suggest the presence of cancer in these cysts.
5. Describe histotripsy and recognize the potential of abscopal effect.
6. Describe indications for evolving techniques in the treatment of metastatic colorectal cancer.
7. Employ complex multidisciplinary discussions in patients with metastatic colorectal cancer given rapidly evolving treatment options that offer hope to patients with previously unresectable disease.

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 7.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cancellation Policy

A full refund will be issued for requests received up to 7 days prior to the conference. No refund will be provided once the conference begins.

The organization holding the activity reserves the right to cancel or postpone this program if necessary; in the event of cancellation, registration fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

Accessibility Statement
University of Arizona College of Medicine - Tucson Office of Continuing Medical Education is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME activity coordinator.

Mitigation of Relevant Financial Relationships

University of Arizona College of Medicine - Tucson Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.